|

FACT Complex-targeting Curaxin CBL0137 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: CBL0137

Pipeline

Phase 1/2: 1

Top Sponsors

  • Children's Oncology Group1

Indications

  • Refractory Primary Malignant Central Nervous System Neoplasm1
  • Recurrent Primary Malignant Central Nervous System Neoplasm1
  • Recurrent Diffuse Midline Glioma, H3 K27-Altered1
  • Metastatic Malignant Neoplasm in the Central Nervous System1
  • Diffuse Midline Glioma, H3 K27-Altered1

Birmingham, Alabama1 trial

CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma

Children's Hospital of Alabama

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.